InterAx Biotech, pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection. InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.